By the numbers: bringing new drugs for allergic/hypersensitivity diseases to the market.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Opinion in Allergy and Clinical Immunology

• Publication date

  2015-06-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1097/ACI.0000000000000170PMID 25899699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinically relevant outcome measures of novel pharmacotherapy for nonallergic rhinitis

  2015cited by this paper
• Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema

  2015cited by this paper
• Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis

  2015cited by this paper
• Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema

  2015cited by this paper
• Clinically relevant outcome measures for new therapies of asthma using pharmaceutical and biologic agents

  2015cited by this paper
• Seeking data and the implicit order that grounds a chaotic world.

  2014cited by this paper
• Treatments for Seasonal Allergic Rhinitis

  2013cited by this paper
• Using Effect Size-or Why the P Value Is Not Enough.

  2012cited by this paper
• Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.

  2011cited by this paper
• How representative are clinical study patients with allergic rhinitis in primary care?

  2011cited by this paper
• The rise of health information technology

  2010cited by this paper
• Personalized care, comparative effectiveness research and the electronic health record

  2010cited by this paper
• Things I Have Learned ( So Far )

  2002cited by this paper

• Expanding Options in House Dust Mite Allergy Immunotherapy: Optimising Individual Patient Outcomes

  2019cites this paper